-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that Rezera is a biotech company that is about to enter phase III clinical trials to develop oral NLRP3 inhibitors for inflammatory diseases. The company announced its IPO terms on Thursday.

Zhitongcaijing·11/06/2026 07:49:08
Listen to the news
The Zhitong Finance App learned that Rezera is a biotech company that is about to enter phase III clinical trials to develop oral NLRP3 inhibitors for inflammatory diseases. The company announced its IPO terms on Thursday.